Beximco Pharmaceuticalshttp://www.beximco-pharma.com/ TICKER: BXP EXCHANGE: AIM
Beximco Pharmaceuticals Ltd (Beximco) is a leading Bangladeshi
manufacturer, marketer and exporter of branded generic finished
pharmaceutical formulations. These come in a wide range of dosage
forms, addressing diverse and growing therapeutic areas. It also
manufactures a number of pharmaceutical active ingredients and
undertakes contract manufacturing. The Company is solely focused
on human health.
Beximco Pharmaceuticals Ltd is a leading Bangladeshi manufacturer, marketer and exporter of branded generic finished pharmaceutical formulations.
Bexinco's prospects look good, with (at least) 15% revenue growth forecast for each of the next 3 financial years.
We think Beximco is currently undervalued based on a ratings' comparison with other quoted pharmaceutical companies. In addition the London-listed GDR's trade at a large discount to the Beximco ordinary shares on the Dhaka exchange.
Foreign buyers gorging on UK stocks
Document can be downloaded here: UK plc â€˜going for a songâ€™
Being a shareholder in a company that receives a juicy takeover offer is a marvellous feeling. Something that many fortunate investors have experienced over the past 3 years. Thanks to a spate of M&A bids by deep pocketed overseas buyers â€“ partly triggered by the June 2016 Brexit result, which sent the Â£ tumbling and adversely affected the FTSE.
Consequently today, given this trend is unlikely to end anytime soon, weâ€™ve highlighted 30 possible acquisition ideas in the attached research paper. Spilt equally between large and smallcap stocks â€“ covering a broad selection of industries.
Whatâ€™s more we believe most of these businesses are underpinned by strong fundamentals and substantial upside in the event of predatory interest.
According to Factset Mergerstat/BVR, the average bid premium paid for such deals between 2004-14 was 30% â€“ with the figure trending upwards since the global financial crisis.
Happy investing. Published 27th August 2019